H.C. Wainwright analyst Arthur He assumed coverage of Aurinia Pharmaceuticals (AUPH) with a Buy rating and $17 price target Aurinia is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases, the analyst tells investors in a research note. The firm believes has a “solid and sustainable” foundation with its lupus nephritis franchise.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUPH: